Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term, Open-label (Dose-blinded), Extension Study of Eptinezumab in Children and Adolescents With Chronic or Episodic Migraine

NCT05164172 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT05164172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05164172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term, Open-label (Dose-blinded), Extension Study of Eptinezumab in Children and Adolescents With Chronic or Episodic Migraine
Lead sponsor
H. Lundbeck A/S
Phase
Phase 3
Overall status
Recruiting
Start date
December 1, 2021
Completion date
April 30, 2028
Enrollment
600 (estimated)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

migraine